10/31/14 ABBV 63.46 Abbvie Inc. Common Stock $ABBV
Post# of 194
Posted On: 11/01/2014 10:19:38 PM
10/31/14 ABBV 63.46 Abbvie Inc. Common Stock $ABBV Hit a 52 week high of 63.99 Closing the day 10/31/14 at 63.46 +2.28 +3.73% With a day low of 62.37 and a total volume of 15,009,800.
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 107.78 (+0.74), VRTX: 112.64 (+1.79), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28)
S&P, Dow Close at Record Highs as U.S. Economic Strength Trumps Global Fears
at The Street - Fri Oct 31, 3:19PM CDT
Global woes plagued markets at the outset of October, but markets are poised to close at a record-high amid strong U.S. economic prospects.
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)
AbbVie Beats Q3 Earnings Estimates, Raises Guidance
at Investor's Business Daily - Fri Oct 31, 1:25PM CDT
Big pharma AbbVie beat analysts' Q3 estimates and raised its guidance Friday, sending its stock up 4% to an all-time high above 63. AbbVie's (ABBV) earnings rose 9% over the year-earlier quarter to 89 cents a share, 12 cents above analysts'...
IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), SHPG: 199.80 (+0.38), AMGN: 162.18 (+0.60), ABBV: 63.46 (+2.28)
Stock Market Today: October Stock Scare Turns to Rally as Dow Hits Record
at The Street - Fri Oct 31, 12:58PM CDT
Fears of an October stock market slump are a distant memory as central banks print money and the U.S. economy kicks into gear.
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)
AbbVie (ABBV) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Oct 31, 12:23PM CDT
The following AbbVie (ABBV) conference call took place on October 31, 2014, 09:00 AM ET. This is a transcript of that earnings call:
ABBV: 63.46 (+2.28)
Stock Market Today: Stocks Hit New Highs as Japan Boosts Stimulus
at The Street - Fri Oct 31, 10:32AM CDT
U.S. stocks surge Friday morning after the Bank of Japan unexpectedly increases its annual stimulus targets.
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)
Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal
at Investor's Business Daily - Fri Oct 31, 10:17AM CDT
Mylan (MYL) was up 3%, near 54, in early trading in the stock market today after the drugmaker beat Q3 estimates late Thursday. Earlier, the stock was up more than 7% at a nearly eight-month high above 56. Earnings came in on the high end of the...
ABT: 43.59 (+0.10), SHPG: 199.80 (+0.38), MYL: 53.55 (+1.18), ABBV: 63.46 (+2.28)
CMK Select Recognized as Women's Business Enterprise
Marketwired - Fri Oct 31, 9:45AM CDT
Since 1997, women-owned businesses have increased in number by 68 percent. CMK Select, a pharmaceuticals business management and consulting services company, is pleased to announce its national certification by the Women's Business Enterprise National Council (WBENC) as a Women's Business Enterprise.
ABBV: 63.46 (+2.28)
AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 9:33AM CDT
AbbVie (ABBV) raised it outlook for 2014 - the new guidance surpassed expectations.
AGN: 190.06 (+0.62), SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79)
Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 107.78 (+0.74), NEE: 100.22 (+0.31), V: 241.43 (+4.78), GILD: 112.00 (-2.22), DUK: 82.15 (-0.14), EXC: 36.59 (-0.11), MRK: 57.94 (+0.63), PFE: 29.95 (+0.11), ABBV: 63.46 (+2.28), DTE: 82.16 (+0.17), SO: 46.36 (-0.09), MA: 83.75 (+0.62)
How AbbVie Inc. Excelled in Third Quarter
Keith Speights, The Motley Fool - Motley Fool - Fri Oct 31, 8:46AM CDT
Make it three in a row. AbbVie beat earnings expectations for the third time this year. The drugmaker announced third-quarter results before the market opened on Friday. Here are the highlights -- and how AbbVie excelled yet again. Source:...
ABBV: 63.46 (+2.28)
Stock Market Today: S&P 500 Is Poised to Open Near Record High on Expanded Bank of Japan Stimulus
at The Street - Fri Oct 31, 7:50AM CDT
U.S. stock futures surge Friday after the Bank of Japan unexpectedly increases its annual stimulus targets by 10 trillion yen to 80 trillion ($717 billion).
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)
AbbVie Reports Third-Quarter 2014 Financial Results
PR Newswire - Fri Oct 31, 6:49AM CDT
AbbVie (NYSE: ABBV) today announced financial results for the third quarter ended Sept. 30, 2014.
ABBV: 63.46 (+2.28)
Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:45PM CDT
Sanofi reported third-quarter 2014 business earnings of 97 cents per ADS, 3 cents above the Zacks Consensus Estimate.
AGN: 190.06 (+0.62), NVO: 45.18 (-1.03), ABBV: 63.46 (+2.28), SNY: 46.24 (+0.54)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79), CRL: 63.16 (+0.35)
Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 67.06 (+2.88), TEVA: 56.47 (unch), AMAG: 33.01 (-0.95), ABBV: 63.46 (+2.28)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.92 (+0.63), VRX: 133.04 (+1.53), ACT: 242.74 (-0.47), AMGN: 162.18 (+0.60), TKMR: 16.68 (-0.26), GSK: 45.49 (+0.35), AGN: 190.06 (+0.62), JNJ: 107.78 (+0.74), SHPG: 199.80 (+0.38), MRK: 57.94 (+0.63), INFI: 13.62 (-0.19), ABBV: 63.46 (+2.28), KPTI: 41.08 (+1.03)
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 190.06 (+0.62), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28)
If You Purchased Shire plc American Depository Receipts ("ADRs"
During The Period Of June 20, 2014 And October 14, 2014 And Lost Money, Gardy & Notis, LLP Encourages You To Contact The Law Firm
PR Newswire - Wed Oct 29, 7:38AM CDT
Gardy & Notis, LLP, a national law firm advocating for shareholder rights, is investigating AbbVie Inc. (NYSE: ABBV) and its officers and directors in connection with statements distributed by, or on behalf of, AbbVie to purchasers of Shire plc ADRs (NASDAQ: SHPG) and the general investing public regarding AbbVie's rationale for pursuing a business combination with Shire.
SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28)
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 107.78 (+0.74), VRTX: 112.64 (+1.79), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28)
S&P, Dow Close at Record Highs as U.S. Economic Strength Trumps Global Fears
at The Street - Fri Oct 31, 3:19PM CDT
Global woes plagued markets at the outset of October, but markets are poised to close at a record-high amid strong U.S. economic prospects.
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)
AbbVie Beats Q3 Earnings Estimates, Raises Guidance
at Investor's Business Daily - Fri Oct 31, 1:25PM CDT
Big pharma AbbVie beat analysts' Q3 estimates and raised its guidance Friday, sending its stock up 4% to an all-time high above 63. AbbVie's (ABBV) earnings rose 9% over the year-earlier quarter to 89 cents a share, 12 cents above analysts'...
IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), SHPG: 199.80 (+0.38), AMGN: 162.18 (+0.60), ABBV: 63.46 (+2.28)
Stock Market Today: October Stock Scare Turns to Rally as Dow Hits Record
at The Street - Fri Oct 31, 12:58PM CDT
Fears of an October stock market slump are a distant memory as central banks print money and the U.S. economy kicks into gear.
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)
AbbVie (ABBV) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Oct 31, 12:23PM CDT
The following AbbVie (ABBV) conference call took place on October 31, 2014, 09:00 AM ET. This is a transcript of that earnings call:
ABBV: 63.46 (+2.28)
Stock Market Today: Stocks Hit New Highs as Japan Boosts Stimulus
at The Street - Fri Oct 31, 10:32AM CDT
U.S. stocks surge Friday morning after the Bank of Japan unexpectedly increases its annual stimulus targets.
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)
Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal
at Investor's Business Daily - Fri Oct 31, 10:17AM CDT
Mylan (MYL) was up 3%, near 54, in early trading in the stock market today after the drugmaker beat Q3 estimates late Thursday. Earlier, the stock was up more than 7% at a nearly eight-month high above 56. Earnings came in on the high end of the...
ABT: 43.59 (+0.10), SHPG: 199.80 (+0.38), MYL: 53.55 (+1.18), ABBV: 63.46 (+2.28)
CMK Select Recognized as Women's Business Enterprise
Marketwired - Fri Oct 31, 9:45AM CDT
Since 1997, women-owned businesses have increased in number by 68 percent. CMK Select, a pharmaceuticals business management and consulting services company, is pleased to announce its national certification by the Women's Business Enterprise National Council (WBENC) as a Women's Business Enterprise.
ABBV: 63.46 (+2.28)
AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 9:33AM CDT
AbbVie (ABBV) raised it outlook for 2014 - the new guidance surpassed expectations.
AGN: 190.06 (+0.62), SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79)
Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 107.78 (+0.74), NEE: 100.22 (+0.31), V: 241.43 (+4.78), GILD: 112.00 (-2.22), DUK: 82.15 (-0.14), EXC: 36.59 (-0.11), MRK: 57.94 (+0.63), PFE: 29.95 (+0.11), ABBV: 63.46 (+2.28), DTE: 82.16 (+0.17), SO: 46.36 (-0.09), MA: 83.75 (+0.62)
How AbbVie Inc. Excelled in Third Quarter
Keith Speights, The Motley Fool - Motley Fool - Fri Oct 31, 8:46AM CDT
Make it three in a row. AbbVie beat earnings expectations for the third time this year. The drugmaker announced third-quarter results before the market opened on Friday. Here are the highlights -- and how AbbVie excelled yet again. Source:...
ABBV: 63.46 (+2.28)
Stock Market Today: S&P 500 Is Poised to Open Near Record High on Expanded Bank of Japan Stimulus
at The Street - Fri Oct 31, 7:50AM CDT
U.S. stock futures surge Friday after the Bank of Japan unexpectedly increases its annual stimulus targets by 10 trillion yen to 80 trillion ($717 billion).
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)
AbbVie Reports Third-Quarter 2014 Financial Results
PR Newswire - Fri Oct 31, 6:49AM CDT
AbbVie (NYSE: ABBV) today announced financial results for the third quarter ended Sept. 30, 2014.
ABBV: 63.46 (+2.28)
Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:45PM CDT
Sanofi reported third-quarter 2014 business earnings of 97 cents per ADS, 3 cents above the Zacks Consensus Estimate.
AGN: 190.06 (+0.62), NVO: 45.18 (-1.03), ABBV: 63.46 (+2.28), SNY: 46.24 (+0.54)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79), CRL: 63.16 (+0.35)
Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 67.06 (+2.88), TEVA: 56.47 (unch), AMAG: 33.01 (-0.95), ABBV: 63.46 (+2.28)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.92 (+0.63), VRX: 133.04 (+1.53), ACT: 242.74 (-0.47), AMGN: 162.18 (+0.60), TKMR: 16.68 (-0.26), GSK: 45.49 (+0.35), AGN: 190.06 (+0.62), JNJ: 107.78 (+0.74), SHPG: 199.80 (+0.38), MRK: 57.94 (+0.63), INFI: 13.62 (-0.19), ABBV: 63.46 (+2.28), KPTI: 41.08 (+1.03)
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 190.06 (+0.62), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28)
If You Purchased Shire plc American Depository Receipts ("ADRs"
During The Period Of June 20, 2014 And October 14, 2014 And Lost Money, Gardy & Notis, LLP Encourages You To Contact The Law Firm PR Newswire - Wed Oct 29, 7:38AM CDT
Gardy & Notis, LLP, a national law firm advocating for shareholder rights, is investigating AbbVie Inc. (NYSE: ABBV) and its officers and directors in connection with statements distributed by, or on behalf of, AbbVie to purchasers of Shire plc ADRs (NASDAQ: SHPG) and the general investing public regarding AbbVie's rationale for pursuing a business combination with Shire.
SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28)
(0)
(0)AbbVie Inc. (ABBV) Stock Research Links
Scroll down for more posts ▼